These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32316878)

  • 1. Impact of a cefepime shortage on dosing regimens and outcomes in hospitalized adults with febrile neutropenia.
    Haiduc M; Patel M; Walsh TL; Moffa MA; Bremmer DN
    J Oncol Pharm Pract; 2021 Mar; 27(2):297-304. PubMed ID: 32316878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
    Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
    J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia.
    Crawford R; Perkins NB; Hobbs DA; Hobbs ALV
    Pharmacotherapy; 2022 Oct; 42(10):798-805. PubMed ID: 36106434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia.
    Okubo L; Andrick B; Rampulla R; Leri F
    J Oncol Pharm Pract; 2022 Jun; 28(4):898-903. PubMed ID: 35156879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies.
    Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5463-9. PubMed ID: 26124158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
    Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
    Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
    Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
    Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.
    Whited L; Grove M; Rose D; Rhodes NJ; Scheetz MH; O'Donnell JN; Neeb J; Thoele K; Jones DR; Lowe C; Moore D; Kiel PJ
    Pharmacotherapy; 2016 Sep; 36(9):1003-10. PubMed ID: 27496678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring.
    Oda K; Yamaguchi A; Matsumoto N; Nakata H; Higuchi Y; Nosaka K; Jono H; Saito H
    Ther Drug Monit; 2024 Feb; 46(1):80-88. PubMed ID: 37735762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
    Ghosh S; Chakraborty M; Samanta S; Sinha N; Saha S; Chattopadhyay A; Roy SS; Bhattacharyya M
    Ann Hematol; 2021 Feb; 100(2):395-403. PubMed ID: 33140134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
    Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
    Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to antibiotics and outcomes in cancer patients with febrile neutropenia.
    Perron T; Emara M; Ahmed S
    BMC Health Serv Res; 2014 Apr; 14():162. PubMed ID: 24716604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
    Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
    J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.